2014 - Page 4 of 5 - Bay City Capital

Filters

Portfolio News

April 22, 2014

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

Portfolio News

April 8, 2014

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS

Portfolio News

April 8, 2014

Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation

Portfolio News

April 8, 2014

Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation

Portfolio News

March 11, 2014

Nevro Corp. Announces Publication of 24-month European Clinical Data on HF10 Spinal Cord Stimulation (SCS) Therapy for Chronic Back and Leg Pain

Portfolio News

March 4, 2014

ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology

Portfolio News

March 3, 2014

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial

Events

February 28, 2014

Haas Business of Healthcare Conference

Panel: Investing in the Life Sciences
Ashley Dombkowski, PhD
February 28, 2014
San Francisco, CA

Portfolio News

February 27, 2014

Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants

Portfolio News

February 27, 2014

Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone

Portfolio News

February 25, 2014

Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology

Portfolio News

February 21, 2014

Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma

Portfolio News

Epizyme Achieves Lead Candidate Milestone for Third Target in GSK Collaboration, Receives $4 Million in Milestone and License Payments

Portfolio News

Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS

Portfolio News

Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation

Portfolio News

Epizyme Granted Patent Covering Diagnosis and Treatment of Cancers Associated with EZH2 Mutation

Portfolio News

Nevro Corp. Announces Publication of 24-month European Clinical Data on HF10 Spinal Cord Stimulation (SCS) Therapy for Chronic Back and Leg Pain

Portfolio News

ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology

Portfolio News

Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial

Events

Haas Business of Healthcare Conference

Portfolio News

Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants

Portfolio News

Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone

Portfolio News

Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology

Portfolio News

Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma

Portfolio News

Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc.

Portfolio News

Teva Expands CNS Specialty Business with Acquisition of NuPathe

Portfolio News

Tria Launches New Age-Defying Laser in the United States